tamibarotene has been researched along with Recrudescence in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (33.33) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asou, N; Fujita, H; Hyo, R; Inaguma, Y; Ishigatsubo, Y; Iwanaga, M; Izumi, T; Kiyoi, H; Matsuda, M; Miyawaki, S; Miyazaki, Y; Nakaseko, C; Naoe, T; Nomura, S; Ohnishi, K; Ohtake, S; Okada, M; Shinagawa, K; Takeshita, A; Yamauchi, T | 1 |
| Fujita, H | 1 |
| Allen, SL; Altman, JK; Cortes, JE; Coutre, S; Di Bona, E; Kantarjian, H; Lo-Coco, F; Ravandi, F; Sanford, D; Sanz, MA; Wetzler, M | 1 |
| Arcese, W; Cudillo, L; Di Veroli, A; Divona, M; Giannì, L; Giannotti, F; Lo-Coco, F; Mirabile, M; Ramadan, SM; Wieland, S | 1 |
| Inoue, A; Kawakami, C; Takitani, K; Tamai, H | 1 |
| Emi, N | 1 |
| Takeuchi, M | 1 |
| Ohnishi, K | 1 |
| Miyawaki, S; Ohnishi, K; Ohno, R; Shibata, Y; Shinjo, K; Shudo, K; Takeshita, A; Tobita, T; Yanagi, M | 1 |
| Harada, M; Kibata, M; Ohno, R; Omoto, E; Shudo, K; Takahashi, K; Takeuchi, M; Ueda, R; Yano, T | 2 |
| Hiraoka, A; Karasuno, T; Kitamura, K; Miyawaki, S; Naoe, T; Ohnishi, K; Ohno, R; Takeshita, A; Takeuchi, M; Tobita, T; Ueda, R; Yanagi, M | 1 |
| Kitamura, K; Kiyoi, H; Naoe, T; Ohno, R; Takeshita, A; Tobita, T; Yoshida, H | 1 |
| Bouda, K; Homma, T; Matsuura, S; Nagai, H; Niwa, S; Shudo, K; Wang, T | 1 |
| Ata, K; Fukutani, H; Hiraoka, A; Miyawaki, S; Ohnishi, K; Ohno, R; Sakura, T; Shinjo, K; Takeshita, A; Takeuchi, M; Tomoyasu, S; Ueda, R; Wakita, H | 1 |
4 review(s) available for tamibarotene and Recrudescence
| Article | Year |
|---|---|
[Treatment for acute promyelocytic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Clinical Trials, Phase III as Topic; Consolidation Chemotherapy; Disseminated Intravascular Coagulation; Gene Fusion; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Molecular Targeted Therapy; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Recurrence; Remission Induction; Retinoic Acid Receptor alpha; Tetrahydronaphthalenes; Transcription Factors; Tretinoin; Tumor Suppressor Proteins | 2014 |
[Clinical experience with a new synthetic retinoid, tamibarotene (Am-80) for relapsed or refractory acute promyelocytic leukemia].
Topics: Benzoates; Cell Differentiation; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Pilot Projects; Recurrence; Remission Induction; Retinoids; Tetrahydronaphthalenes | 2006 |
[Therapeutic strategies for patients with relapsed acute promyelocytic leukemia].
Topics: Aminoglycosides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Leukemia, Promyelocytic, Acute; Oxides; Practice Guidelines as Topic; Recurrence; Remission Induction; Tetrahydronaphthalenes; Tretinoin | 2006 |
Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am-80.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Benzoates; Biomarkers, Tumor; Cheilitis; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Hypercholesterolemia; Hypertriglyceridemia; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Pilot Projects; Recurrence; Remission Induction; Salvage Therapy; Tetrahydronaphthalenes; Treatment Outcome; Tretinoin; Tumor Cells, Cultured | 1998 |
5 trial(s) available for tamibarotene and Recrudescence
| Article | Year |
|---|---|
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Biomarkers, Tumor; Cardiovascular Diseases; Cell Differentiation; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; Drug Resistance, Neoplasm; Febrile Neutropenia; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Salvage Therapy; Tetrahydronaphthalenes; Tretinoin | 2015 |
Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Cell Differentiation; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Female; Gastrointestinal Diseases; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Pain; Prospective Studies; Receptors, Retinoic Acid; Recurrence; Remission Induction; Retinoic Acid Receptor gamma; Retinoids; Salvage Therapy; Tetrahydronaphthalenes; Treatment Outcome; Tretinoin | 1997 |
New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Retinoids; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured | 1997 |
Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am-80.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Benzoates; Biomarkers, Tumor; Cheilitis; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Hypercholesterolemia; Hypertriglyceridemia; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Pilot Projects; Recurrence; Remission Induction; Salvage Therapy; Tetrahydronaphthalenes; Treatment Outcome; Tretinoin; Tumor Cells, Cultured | 1998 |
Good prognosis of patients with acute promyelocytic leukemia who achieved second complete remission (CR) with a new retinoid, Am80, after relapse from CR induced by all-trans-retinoic acid.
Topics: Adult; Aged; Antineoplastic Agents; Benzoates; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Prognosis; Recurrence; Remission Induction; Retinoids; Tetrahydronaphthalenes; Tretinoin | 2000 |
7 other study(ies) available for tamibarotene and Recrudescence
| Article | Year |
|---|---|
Role of hematopoietic stem cell transplantation for relapsed acute promyelocytic leukemia: a retrospective analysis of JALSG-APL97.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Combined Modality Therapy; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Japan; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Retrospective Studies; Salvage Therapy; Tetrahydronaphthalenes; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Tretinoin; Young Adult | 2013 |
Molecular remission in advanced acute promyelocytic leukaemia after treatment with the oral synthetic retinoid Tamibarotene.
Topics: Adult; Antineoplastic Agents; Benzoates; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Recurrence; Tetrahydronaphthalenes | 2010 |
Sustained molecular remission after arsenic trioxide and gemutuzumab ozogamicin in a pediatric patient with relapsed acute promyelocytic leukemia.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; Benzoates; Child; Drug Administration Schedule; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence; Remission Induction; Tetrahydronaphthalenes; Tretinoin | 2012 |
[Management of relapsed acute promyelocytic leukemia].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Brain; Humans; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Oxides; Recurrence; Tetrahydronaphthalenes | 2012 |
Successful treatment of relapse of acute promyelocytic leukemia with a new synthetic retinoid, Am80.
Topics: Adult; Benzoates; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Recurrence; Remission Induction; Retinoids; Tetrahydronaphthalenes | 1996 |
Re-induction of complete remission with a new synthetic retinoid, Am-80, for relapse of acute promyelocytic leukaemia previously treated with all-trans retinoic acid.
Topics: Adult; Benzoates; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Recurrence; Remission Induction; Tetrahydronaphthalenes; Tretinoin | 1997 |
The effect of Am-80, one of retinoids derivatives on experimental allergic encephalomyelitis in rats.
Topics: Administration, Oral; Animals; Benzoates; Disease Models, Animal; Dose-Response Relationship, Drug; Ear, External; Encephalomyelitis, Autoimmune, Experimental; Female; Hypersensitivity, Delayed; Interferon-gamma; Interleukin-6; Myelin Basic Protein; Prednisolone; Rats; Recurrence; Retinoids; RNA, Messenger; Spinal Cord; Tetrahydronaphthalenes; Tumor Necrosis Factor-alpha | 2000 |